Esab Corp.
Congress has disclosed 4 buys and 0 sells of ESAB (Esab Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying ESAB and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Thomas Kean | 2026-09-29 | $67.48 | $69.76 | +3.4% | ↩ near entry |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Industrials. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
4 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2026-09-29 | 2 days | -0.7% | $1K–$15K 0.1% of NW |
63.4 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2026-07-07 | 27 days | -3.2% | $1K–$15K 0.1% of NW |
29.6 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2026-06-24 | 7 days | -3.3% | $1K–$15K 0.1% of NW |
47.6 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2026-06-22 | 9 days | -8.4% | $1K–$15K 0.1% of NW |
69.0 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in ESAB — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in ESAB, 0 coincided with corporate insiders moving the same way within 60 days, and 4 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-08-07 | Jordan Rhonda L | Director | SELL | $95K | ↗ EDGAR |
| 2026-02-27 | Campion Michele | C-suite | SELL 10b5-1 | $270K | ↗ EDGAR |
| 2026-02-27 | Campion Michele | C-suite | SELL 10b5-1 | $355K | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $4.0M | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $1.6M | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $1.4M | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $164K | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $77K | ↗ EDGAR |
| 2026-02-23 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $219K | ↗ EDGAR |
| 2026-02-06 | Johnson Kevin J | C-suite | SELL 10b5-1 | $470K | ↗ EDGAR |
| 2025-11-11 | Vinnakota Rajiv | Director | SELL | $319K | ↗ EDGAR |
| 2025-08-13 | Jordan Rhonda L | Director | SELL | $460K | ↗ EDGAR |
| 2025-08-11 | Cummings Melissa | Director | BUY | $5K | ↗ EDGAR |
| 2025-07-31 | Biebuyck Olivier | C-suite | SELL 10b5-1 | $192K | ↗ EDGAR |
| 2025-06-11 | Jordan Rhonda L | Director | SELL | $190K | ↗ EDGAR |
| 2025-05-12 | Biebuyck Olivier | C-suite | SELL 10b5-1 | $186K | ↗ EDGAR |
| 2025-03-10 | Teirlinck Didier P | Director | SELL | $199K | ↗ EDGAR |
| 2025-02-28 | Vinnakota Rajiv | Director | SELL | $262K | ↗ EDGAR |
| 2024-10-30 | Jordan Rhonda L | Director | SELL | $532K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $301K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $146K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $245K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $391K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $408K | ↗ EDGAR |
| 2024-10-29 | Kambeyanda Shyam | C-suite | SELL 10b5-1 | $54K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| Congress | 2026-09-29 | Thomas Kean | BUY | $1K–$15K |
| ◆ insider | 2026-08-07 | Jordan Rhonda L Director | SELL | $95K |
| Congress | 2026-07-07 | Thomas Kean | BUY | $1K–$15K |
| Congress | 2026-06-24 | Thomas Kean | BUY | $1K–$15K |
| Congress | 2026-06-22 | Thomas Kean | BUY | $1K–$15K |
| ◆ insider | 2026-02-27 | Campion Michele C-suite 10b5-1 | SELL | $270K |
| ◆ insider | 2026-02-27 | Campion Michele C-suite 10b5-1 | SELL | $355K |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $4.0M |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $1.6M |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $1.4M |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $164K |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $77K |
| ◆ insider | 2026-02-23 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $219K |
| ◆ insider | 2026-02-06 | Johnson Kevin J C-suite 10b5-1 | SELL | $470K |
| ◆ insider | 2025-11-11 | Vinnakota Rajiv Director | SELL | $319K |
| ◆ insider | 2025-08-13 | Jordan Rhonda L Director | SELL | $460K |
| ◆ insider | 2025-08-11 | Cummings Melissa Director | BUY | $5K |
| ◆ insider | 2025-07-31 | Biebuyck Olivier C-suite 10b5-1 | SELL | $192K |
| ◆ insider | 2025-06-11 | Jordan Rhonda L Director | SELL | $190K |
| ◆ insider | 2025-05-12 | Biebuyck Olivier C-suite 10b5-1 | SELL | $186K |
| ◆ insider | 2025-03-10 | Teirlinck Didier P Director | SELL | $199K |
| ◆ insider | 2025-02-28 | Vinnakota Rajiv Director | SELL | $262K |
| ◆ insider | 2024-10-30 | Jordan Rhonda L Director | SELL | $532K |
| ◆ insider | 2024-10-29 | Kambeyanda Shyam C-suite 10b5-1 | SELL | $301K |
FAQ Common questions
How much has Congress traded ESAB?
4 disclosed buys and 0 sells of ESAB (Esab Corp.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade ESAB?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.